Fresenius AGM: Shareholders Overwhelmingly Back #FutureFresenius Agenda

Fresenius AGM: Shareholders Overwhelmingly Back #FutureFresenius Agenda

(IN BRIEF) At the Annual General Meeting in Frankfurt am Main, shareholders of Fresenius SE & Co. KGaA overwhelmingly approved proposals from the General Partner and the Supervisory Board. Chairman of the Supervisory Board, Wolfgang Kirsch, commended Fresenius’ resilience amidst geopolitical challenges and highlighted the success of the #FutureFresenius program in strengthening the company sustainably. CEO Michael Sen expressed gratitude for shareholder support and emphasized the commitment to advancing #FutureFresenius initiatives. With 99.84% backing for the annual financial statements and strong approval for the Compensation Report and actions of both the Management Board and the Supervisory Board, Fresenius is poised to pursue its ambitious corporate goals with optimism and motivation.

(PRESS RELEASE) BAD HOMBURG, 18-May-2024 — /EuropaWire/ — At Annual General Meeting in Frankfurt am Main, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board by a large majority.

Wolfgang Kirsch, Chairman of the Supervisory Board, thanked the Management Board and emphasized Fresenius’ strong performance in extremely challenging geopolitical times. “Against this backdrop, Fresenius has performed well as a leading healthcare company compared to the competition and has improved significantly in operational terms.” He added that the #FutureFresenius program is strengthening Fresenius sustainably in the interests of all stakeholders. “The new Management Board team under the leadership of Michael Sen brings experience and complementary skills, team spirit and abilities, which will allow us to achieve the ambitious corporate goals and successfully implement #FutureFresenius,” said Kirsch.

CEO Michael Sen thanked the shareholders for supporting the #FutureFresenius journey, as well as the members of the Supervisory Board and Chairman Wolfgang Kirsch for their excellent cooperation. “We have successfully completed the first phases of #FutureFresenius and regained trust. We shall now tackle the remaining phases with motivation and optimism,” he stressed.

A large majority of 99.84% of shareholders voted in favor of approving the annual financial statements. The shareholders approved the Compensation Report for the 2023 fiscal year by 93.06%. Large majorities of 96.48% and 95.90% respectively approved the actions of the Management Board and the Supervisory Board in 2023.

At the Annual General Meeting of Fresenius SE & Co. KGaA, 72.65% of the registered capital was represented.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those currently expected due to various risk factors and uncertainties, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Media Contact:

Timo Lindemann
Tel: +49 6172 608-7939
email: timo.lindemann@fresenius.com

SOURCE: Fresenius SE & Co. KGaA